Envista (NYSE:NVST) Reaches New 12-Month High Following Analyst Upgrade

Envista Holdings Corporation (NYSE:NVST) reached a new 52-week high during trading on Thursday after Barclays raised their price target on the stock from $24.00 to $34.00. Barclays currently has an overweight rating on the stock. Envista traded as high as $30.42 and last traded at $30.1890, with a volume of 3500017 shares traded. The stock had previously closed at $30.17.

A number of other research analysts have also recently commented on NVST. Wells Fargo & Company boosted their price target on Envista from $21.00 to $26.00 and gave the stock an “equal weight” rating in a report on Friday, February 6th. Mizuho lifted their price objective on shares of Envista from $24.00 to $27.00 and gave the company a “neutral” rating in a research report on Tuesday. Evercore ISI set a $32.00 target price on shares of Envista and gave the stock an “outperform” rating in a report on Friday, February 6th. William Blair upgraded shares of Envista from a “hold” rating to an “outperform” rating in a report on Friday, February 6th. Finally, UBS Group raised their price objective on Envista from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.43.

Insider Transactions at Envista

In other news, SVP Mischa Reis sold 9,675 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total value of $290,250.00. Following the completion of the sale, the senior vice president directly owned 32,382 shares of the company’s stock, valued at $971,460. This trade represents a 23.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.66% of the stock is currently owned by company insiders.

Key Headlines Impacting Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Barclays raised its price target from $24 to $34 and moved NVST to an “overweight” rating, signaling stronger institutional conviction and giving the stock more upside momentum. Article Title
• Positive Sentiment: Short interest dropped ~23.3% in January to ~8.09M shares (about 5.0% of float, 3.1 days to cover), reducing one bearish force and removing a potential short-squeeze overhang. (Data reported 2/10/2026)
• Positive Sentiment: Zacks and other broker commentary have highlighted NVST as a buy/upgrade candidate amid sector rotation and AI-related market noise, reinforcing the positive analyst narrative around growth and execution. Article Title
• Positive Sentiment: Coverage highlighting Envista as a strong growth stock and noting that the name is gaining renewed focus as healthcare/NYSE composites strengthen, supporting continued investor interest. Article Title
• Neutral Sentiment: Mizuho raised its price target from $24 to $27 but kept a “neutral” rating — a modest improvement but still below the current market level, which may temper upside expectations for some investors. Article Title
• Negative Sentiment: Insider selling: SVP Mischa Reis sold 9,675 shares at about $30 (roughly $290K), reducing her stake by ~23%. Insider sales can create short-term nervousness about insider conviction even when not uncommon. SEC Filing

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NVST. Royal Bank of Canada increased its position in Envista by 26.6% during the first quarter. Royal Bank of Canada now owns 23,240 shares of the company’s stock valued at $401,000 after acquiring an additional 4,885 shares during the last quarter. Millennium Management LLC grew its holdings in Envista by 218.6% during the 1st quarter. Millennium Management LLC now owns 383,966 shares of the company’s stock valued at $6,627,000 after purchasing an additional 263,442 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Envista by 39.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 629,140 shares of the company’s stock worth $10,859,000 after purchasing an additional 177,630 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Envista by 15.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 568,982 shares of the company’s stock worth $9,821,000 after purchasing an additional 76,246 shares during the last quarter. Finally, KLP Kapitalforvaltning AS lifted its stake in Envista by 11.3% in the second quarter. KLP Kapitalforvaltning AS now owns 36,400 shares of the company’s stock worth $711,000 after purchasing an additional 3,700 shares during the last quarter.

Envista Stock Up 0.1%

The firm has a market cap of $4.96 billion, a PE ratio of 107.82, a price-to-earnings-growth ratio of 2.06 and a beta of 1.01. The company has a 50-day simple moving average of $23.36 and a 200-day simple moving average of $21.43. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.38 and a quick ratio of 2.04.

Envista (NYSE:NVST) last posted its quarterly earnings results on Thursday, February 5th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. The firm had revenue of $750.60 million for the quarter, compared to analysts’ expectations of $680.26 million. Envista had a net margin of 1.73% and a return on equity of 6.54%. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Analysts expect that Envista Holdings Corporation will post 1 earnings per share for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.